ofa vs fda tirzepatide FDA's Removal of Semaglutide and the Evolving Decisions: What Compounders Need to Know Where things stand (for now): – FDA Faces Law Suit Over

& Hsu, C.-Y

For patients taking warfarin, more frequent INR monitoring is recommended during semaglutide initiation or dose changes, as a prudent clinical practice

Public Enquiries: (613) 957-2991, 866 225-0709, [email protected]

It is also known to be closely related to the T2MD metabolic syndrome, and the morbidity and mortality of CVDs (183, 184)

Improvement of at least one fibrosis stage without worsening of MASH occurred in 51-55% of tirzepatide-treated participants versus 30% with placebo

Although causality is debated and absolute risk is low, clinicians should be alert to severe abdominal pain and elevated pancreatic enzymes and stop therapy if pancreatitis is suspected